Inovio Voceryq FDA approval extends Precigen premarket drop after Friday plunge

 

• FDA granted accelerated approval Oct 30 to Inovio Voceryq for RRP, competing with Precigen PAPZIMEOS.
• Precigen shares fell about 27% after-hours Friday from the $6.94 close on the news.
• Premarket Monday continues the decline, last at $5.58 versus Friday previous close.
• No new Precigen press releases, SEC filings or analyst notes overnight or Sunday.
• Earnings report due Nov 4 after close; Inovio holds an 8 AM ET call on the approval.
• Retail chatter on Stocktwits notes possible buyout interest and first-mover advantages.

https://finviz.com/stock?t=PGEN&p=d